Key Insights

Highlights

Treatment Research

1 treatments under study, led by Stmc103h

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03819881Phase 1UnknownPrimary

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

Showing all 1 trials

Research Network

Common Treatments

  • Stmc103h1

Active Sponsors

  • Siolta Therapeutics, Inc.1
  • Integrium1

Top Investigators

Activity Timeline